Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
A Multicentric Phase I/II Study of Jaktinib Hydrochloride Tablets in Combination With Azacitidine for Injection in Patients With Myelodysplastic Syndromes(MDS) With Myelofibrosis(MF) or MDS/Myeloproliferative Neoplasms With MF
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Terminated
Corporate policy adjustments
Other terminated trials from Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- ALK-positive Non-small Cell Lung Cancer · Phase PHASE2 · Oct 2022
- Acute Myeloid Leukemia (AML) · Phase PHASE1 · Feb 2022
- Nasopharyngeal Carcinoma · Phase PHASE1/PHASE2 · Oct 2021
- Differentiated Thyroid Cancer · Phase PHASE3 · Jul 2021
- Oesophageal Cancer · Phase PHASE1/PHASE2 · Oct 2020
More terminations from Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Other Myelodysplastic Syndromes trials with similar outcome
Listed as NCT04866056, this PHASE1/PHASE2 trial focuses on Myelodysplastic Syndromes and Myelofibrosis and remains terminated or withdrawn. Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, it has been updated 6 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Not Yet Recruiting → Terminated
-
Jan 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Sep 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
▶ Show 1 earlier version
-
May 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
For direct contact, visit the study record on ClinicalTrials.gov .